Alzamend Neuro, Inc. (ALZN)
| Market Cap | 5.01M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -12.40M |
| Shares Out | 6.87M |
| EPS (ttm) | -1.87 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 9,457 |
| Open | 0.705 |
| Previous Close | 0.726 |
| Day's Range | 0.705 - 0.730 |
| 52-Week Range | 0.652 - 11.910 |
| Beta | 0.02 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Mar 25, 2024 |
About ALZN
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a ... [Read more]
Financial Performance
Financial StatementsNews
Alzamend Neuro Regains Compliance with Nasdaq's Minimum Bid Price Requirement
ATLANTA--(BUSINESS WIRE)---- $ALZN #Alzamend--Alzamend Neuro Regains Compliance with Nasdaq's Minimum Bid Price Requirement.
Alzamend Neuro Announces Reverse Stock Split
ATLANTA--(BUSINESS WIRE)---- $ALZN #15_to_1_stock_reversal--Alzamend Neuro Announces Reverse Stock Split.
Altasciences Completes Clinical Portion of Alzamend Neuro's Phase IIa Multiple Ascending Dose Clinical Trial for Treatment of Dementia Related to Alzheimer's
LAVAL, Québec--(BUSINESS WIRE)-- #Altasciences--Altasciences is proud to support Alzamend Neuro, Inc. (Alzamend) in advancing a novel treatment for dementia related to Alzheimer's disease (Alzheimer's...
Ault Alliance Announces Alzamend Neuro Has Initiated Its Phase I/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer's Type
LAS VEGAS--(BUSINESS WIRE)---- $ALZN #ALZN--Ault Alliance Announces Alzamend Neuro Initiated Its Phase I/IIA Trial for Immunotherapy Vaccine ALZN002 to Treat Mild to Moderate Alzheimer's Disease
BitNile Holdings Contemplates Exchange Offer to Acquire Shares of Its Common Stock
LAS VEGAS--(BUSINESS WIRE)--BitNile Holdings, Inc. (NYSE American: NILE), a diversified holding company (“BitNile” or the “Company”), today announced that the Company is considering undertaking an e...
In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews Stephan Jackman, CEO Alzamend Neuro, Inc.
NEW YORK, NY / ACCESSWIRE / November 22, 2022 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap publicly traded companies recently iss...
BitNile Holdings Reports Third Quarter 2022 Financial Results, Including Revenue of $100 Million for the Nine Months Ended September 30, 2022, up 124% from the Prior Year's Nine-Month Period
LAS VEGAS--(BUSINESS WIRE)--BitNile Holdings, Inc. (NYSE American: NILE), a diversified holding company (“BitNile” or the “Company”), reported its financial results for the third quarter ended Septe...
BitNile Holdings Announces That Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase I/IIA Clinical Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Alzheimer's Disease
LAS VEGAS--(BUSINESS WIRE)---- $ALZN #ALZN--BitNile Holdings, Inc. (NYSE American: NILE), a diversified holding company (“BitNile” or the “Company”) today announced that Alzamend Neuro, Inc. (Nasdaq: ...
Alzamend Neuro Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement
ATLANTA--(BUSINESS WIRE)---- $ALZN #Alzamend--Alzamend Neuro Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement
Alzamend Neuro Shares Are Trading Higher After Encourage Early-Stage Data From Alzheimer's Candidate
Alzamend Neuro Inc (NASDAQ: ALZN) has posted positive topline data from its Phase 1 trial for AL001 as an oral treatment for dementia-related to Alzheimer's disease. The trial was designed to determin...
See Why Alzamend Neuro Stock Is Rallying On Thursday
Alzamend Neuro Inc (NASDAQ: ALZN) has received a written response to its meeting request regarding the FDA's Type B Pre‑Investigational New Drug (Pre-IND) application. Today's response provides a path...
Why Alzamend Neuro Shares Are Surging Higher Today
Alzamend Neuro Inc (NASDAQ: ALZN) is surging higher Thursday after the company announced it received a written response to its meeting request relating to its Type B Pre‑IND application from the FDA p...
Alzamend Neuro Receives Positive Pre-IND Response from FDA for AL002, a Cell-Based Therapeutic Vaccine That Seeks to Restore the Ability of Patients' Immunological System to Combat Alzheimer's Disease
TAMPA, Fla.--(BUSINESS WIRE)---- $AMEX #2nd_Treatment_to_Clinic--Alzamend Neuro Gets Positive FDA Pre-IND Response for AL002, a Therapeutic Vaccine that Seeks to Restore Patient's Immuno System to Com...
Alzamend Neuro Announces Initiation of Phase I First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer's Disease
TAMPA, Fla.--(BUSINESS WIRE)---- $AMEX #505b2--Alzamend Neuro Initiates Phase I First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer's Disease; Doses First Participant Group
Alzamend Neuro Announces Additional Investment Under Its Investigational New Drug Application for AL001 for Dementia Related to Alzheimer's Pursuant to the Securities Purchase Agreement with Digital Power Lending
TAMPA, Fla.--(BUSINESS WIRE)---- $AMEX #505b2--Alzamend Neuro Receives Additional $2M Investment from Digital Power Lending Due to Its IND Application for AL001 for Dementia Related to Alzheimers
Alzamend Neuro Announces Pre-IND Submission for AL002 as a Cell-Based Therapeutic Vaccine That Seeks to Restore the Ability of Patient's Immunological System to Combat Alzheimer's
TAMPA, Fla.--(BUSINESS WIRE)---- $AMEX #505b2--Alzamend Neuro Submits Pre-IND for AL002 as Therapeutic Vaccine That Seeks to Restore Ability of Patient's Immunological System to Combat Alzheimer's
Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase 1 Clinical Study Under Its Investigational New Drug Application for AL001 for Dementia Related to Alzheimer's Disease
TAMPA, Fla.--(BUSINESS WIRE)---- $AMEX #505b2--Alzamend Neuro Receives FDA “Study May Proceed” Letter for AL001 Phase 1 Clinical Study Investigational New Drug Application for Alzheimer's Disease
Alzamend Neuro Stock Shoots Higher As Alzheimer's Candidate Shows Encouraging Safety Profile In Animal Models
Alzamend Neuro Inc (NASDAQ: ALZN) has announced positive toxicology results for AL002 in a toxicology study using a transgenic mouse model of Alzheimer's disease. Charles River Laboratories conducted...
Alzamend Neuro Receives Positive Results for AL002 in a GLP Toxicology Study Using a Transgenic Mouse Model of Alzheimer's Disease
TAMPA, Fla.--(BUSINESS WIRE)---- $AMEX #505b2--Alzamend Neuro Receives Positive Results for AL002, a Mutant-Peptide Vaccine, in GLP CRL Tox Study Using Alzheimer's Disease Transgenic Mouse Model
Alzamend Neuro, Inc. to Ring Nasdaq Opening Bell Today
TAMPA, Fla.--(BUSINESS WIRE)---- $ALZN #505b2--Alzamend Neuro, Inc. to Ring Nasdaq Opening Bell Today at 9:15am ET; Alzamend Celebrates Successful Initial Public Offering and Corporate Milestone
Alzamend Neuro Submits IND Application For Alzheimer's-Related Dementia Candidate
Ault Global Holdings Inc (NYSE: DPW), a diversified holding company, has announced that Alzamend Neuro Inc (NASDAQ: ALZN) has submitted an investigational new drug application to the FDA for a Phase 1...
Alzamend Neuro Submits IND Application for AL001 for Dementia Related to Alzheimer's Disease
TAMPA, Fla.--(BUSINESS WIRE)---- $AMEX #505b2--Alzamend Neuro Submits IND Application to the FDA for AL001, a lithium-based ionic cocrystal oral therapy for Dementia Related to Alzheimer's Disease
Alzamend Neuro Announces Closing of Initial Public Offering and Full Exercise of Underwriter's Over-allotment Option for Gross Proceeds of $14.4 Million
TAMPA, Fla.--(BUSINESS WIRE)---- $AMEX #ADDF--Alzamend Neuro Announces Closing of Initial Public Offering & Full Exercise of Underwriter's Over-allotment Option for Gross Proceeds of $14.4 Million
Ault Global Holdings Announces Alzamend Neuro Pricing of Initial Public Offering
LAS VEGAS--(BUSINESS WIRE)---- $AGH #AP--Ault Global Holdings Announces Alzamend Neuro (Nasdaq: ALZN) Pricing of Initial Public Offering of 2,500,000 Shares of Common Stock at $5.00 per Share
Alzamend Neuro Announces Pricing of Initial Public Offering
TAMPA, Fla.--(BUSINESS WIRE)---- $AMEX #ADDF--Alzamend Neuro Announces Pricing of Initial Public Offering of 2,500,000 Shares of its Common Stock at a Price to the Public of $5.00 per Share